Business Description
Dyne Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US26818M1080
Share Class Description:
DYN: Ordinary SharesTotal Employee Number:
258Description
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.1 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.31 | |||||
Debt-to-EBITDA | -0.44 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -1.5 | |||||
3-Year EPS without NRI Growth Rate | -2.4 | |||||
3-Year FCF Growth Rate | -3.1 | |||||
3-Year Book Growth Rate | 9.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.6 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 3.44 | |||||
9-Day RSI | 10.06 | |||||
14-Day RSI | 18.52 | |||||
3-1 Month Momentum % | 49.97 | |||||
6-1 Month Momentum % | 33.97 | |||||
12-1 Month Momentum % | 99.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.02 | |||||
Quick Ratio | 12.02 | |||||
Cash Ratio | 11.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -43.7 | |||||
Shareholder Yield % | -20.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -68.3 | |||||
ROA % | -53.47 | |||||
ROIC % | -857.58 | |||||
3-Year ROIIC % | -1484.25 | |||||
ROC (Joel Greenblatt) % | -1201.79 | |||||
ROCE % | -55.13 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.35 | |||||
Price-to-Tangible-Book | 4.34 | |||||
EV-to-EBIT | -5.47 | |||||
EV-to-EBITDA | -5.5 | |||||
EV-to-Forward-Revenue | 68.59 | |||||
EV-to-FCF | -5.53 | |||||
| Price-to-Net-Current-Asset-Value | 4.72 | |||||
| Price-to-Net-Cash | 5.03 | |||||
Earnings Yield (Greenblatt) % | -18.28 | |||||
FCF Yield % | -14.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DYN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dyne Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.33 | ||
| Beta | 2.3305 | ||
| 3-Year Sharpe Ratio | 0.63 | ||
| 3-Year Sortino Ratio | 1.29 | ||
| Volatility % | 85.25 | ||
| 14-Day RSI | 18.52 | ||
| 14-Day ATR ($) | 1.430903 | ||
| 20-Day SMA ($) | 24.767 | ||
| 12-1 Month Momentum % | 99.55 | ||
| 52-Week Range ($) | 11.92 - 27.305 | ||
| Shares Outstanding (Mil) | 186.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dyne Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dyne Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-02 | In 172 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-02 | In 172 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 55 days | ||
| Guidance call for 2026 | 2026-09-15 10:50 | In 5 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 09:15 | In 4 days | ||
| Guidance call for 2026 | 2026-09-11 10:20 | In 1 day | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 25.90 (+1.89%) | ||
| Guidance call for 2026 | 2026-06-09 | 16.81 (-2.72%) | ||
| General meeting for 2026 | 2026-06-05 11:00 | 18.41 (+1.43%) | ||
| Guidance call for 2026 | 2026-06-03 09:55 | 17.24 (-5.79%) |
Show
Entries
Dyne Therapeutics Inc Frequently Asked Questions
What is Dyne Therapeutics Inc(DYN)'s stock price today?
The current price of DYN is $18.42. The 52 week high of DYN is $27.31 and 52 week low is $11.92.
When is next earnings date of Dyne Therapeutics Inc(DYN)?
The next earnings date of Dyne Therapeutics Inc(DYN) is 2026-11-05 Est..
Does Dyne Therapeutics Inc(DYN) pay dividends? If so, how much?
Dyne Therapeutics Inc(DYN) does not pay dividend.
Press Release
Headlines
See More- 1
Sep 09, 2026
Dyne extends slide as J.P. Morgan downgrades on Novartis setback
Seeking Alpha • 8:20am
Sep 08, 2026
Biggest stock movers Tuesday: ZIM, NVS, and more
Seeking Alpha • 4:23am
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
Seeking Alpha • 3:56am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers